688505.SS Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (30 Apr 2024 @ 09:00):

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products...

Stats
Tagesvolumen	2.95M
Durchschnittsvolumen	3.20M
Marktkapitalisierung	652.35M
EPS	CNY0 ( 2024-04-29 )
Last Dividend	CNY0 ( N/A )
Next Dividend	CNY0 ( N/A )
P/E	70.27
ATR14	CNY0.0100 (0.13%)

Volumen Korrelation

Lang: 0.14 (neutral)

Kurz: -0.49 (neutral)

Signal:(39.4) Neutral

Shanghai Fudan-Zhangjiang Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Shanghai Fudan-Zhangjiang Korrelation - Währung/Rohstoff

0.14
( neutral )

-0.30
( neutral )

0.00
( neutral )

0.24
( neutral )

0.18
( neutral )

0.54
( weak )

Shanghai Fudan-Zhangjiang Finanzdaten

Annual	2023
Umsatz:	CNY845.34M
Bruttogewinn:	CNY735.99M (87.06 %)
EPS:	CNY0.110

FY	2023
Umsatz:	CNY845.34M
Bruttogewinn:	CNY735.99M (87.06 %)
EPS:	CNY0.110

FY	2022
Umsatz:	CNY1.03B
Bruttogewinn:	CNY947.10M (91.85 %)
EPS:	CNY0.130

FY	2021
Umsatz:	CNY1.14B
Bruttogewinn:	CNY1.06B (92.90 %)
EPS:	CNY0.220

Financial Reports:

No articles found.

Shanghai Fudan-Zhangjiang

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products. It offers genetic engineering platform drugs, including CD30-DM1 antibody-drug conjugate (ADC), which is in Phase I clinical trials for tumors; Trop2-SN38 ADC that is in Phase I clinical trials for triple negative, breast, bladder, gastric, and other tumors; Trop2-BB05 ADC that is in pre-clinical studies for lung cancer and triple negative breast cancer; and HER2 ADC that has completed pre-clinical research for metastatic breast and gastric cancers. The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which is in Phase IV clinical trial; and aminolevulinic acid, which is in Phase II clinical trials for cervical diseases infected by HPV and acne, as well as completed pre-clinical study for brain gliomas. In addition, it offers nano technical platform drugs, such as Nanoparticle Albumin-bound Paclitaxel that is in pre-clinical studies for tumors, as well as developing Doxorubicin liposome for tumors. Further, the company offers oral solid preparation technology, which includes obeticholic acid for hepatobiliary and autoimmune disease; timolol maleate cream that is in pre-clinical studies for infantile hemangioma; and FZJ-003 oral preparation, which is in Phase I clinical trials for rheumatoid arthritis, as well as in Phase II clinical trials for atopic dermatitis and ulcerative colitis. Additionally, it develops pharmaceutical and medical devices; medical diagnostic products and related services; and sells daily necessities, and clinical laboratory analysis instruments and software. It also engages in the technology development, transfer, consulting, and promotion activities; produces freeze-dried powder injections and APIs; and invests in overseas medical projects. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.